Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.

Int J Biol Sci · 2022 · PMC9295068 · PMID 35864956

Europe PMC DOI

hedged sentence

0.5900

closest p · 11.8× alpha

0.5900

boldest claim

The sentences

a very slight trend toward significancep=0.59not close (p > 0.1)

In addition, high-DUSP4 HCC patients in the course of Sorafenib treatment had a better OS with a very slight trend toward significance (p=0.59) than low-DUSP4 HCC patients ( Figure S7 B ).

also in 5 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.